Wixela inhaler prices vary depending on factors such as insurance coverage, pharmacy, and whether a discount card or coupon is used. The average retail price for a 30-day supply of Wixela Inhub, which contains fluticasone propionate and salmeterol, is approximately $380 to $400 [1].
How can I find discounts for Wixela?
Patients may be able to reduce the cost of Wixela through discount programs. The manufacturer, GlaxoSmithKline (GSK), offers a Wixela Inhub Savings Card, which can provide eligible commercially insured patients with savings of up to $75 per prescription refill, with a maximum annual saving of $900 [2]. This card is available through the Wixela website or by asking a pharmacist [2].
When does Wixela Inhub's patent expire?
The patent landscape for Wixela Inhub is complex. While the primary patents may have expired or are nearing expiration, patent litigation can extend market exclusivity. DrugPatentWatch.com tracks patent information for various medications, including those with similar active ingredients to Wixela [3].
What are the alternatives to Wixela Inhub?
Wixela Inhub is a combination inhaler containing fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-agonist). Alternatives include other branded and generic inhalers that offer the same or similar combinations of these medications. Some common alternatives include Advair Diskus and Advair HFA, which contain the same active ingredients as Wixela [4]. Generic versions of fluticasone propionate and salmeterol inhalers are also available and may offer a lower cost option.
Can I get Wixela Inhub covered by insurance?
Insurance coverage for Wixela Inhub varies by plan. Most insurance providers cover maintenance inhalers for asthma and COPD, but the specific formulary status and copay amounts can differ. It is advisable to check with your insurance provider or pharmacist to confirm coverage and estimate your out-of-pocket costs.
What is the difference between Wixela Inhub and Advair?
Wixela Inhub and Advair Diskus are both inhalation devices containing fluticasone propionate and salmeterol. They are therapeutically equivalent, meaning they are expected to have the same clinical effect. The primary difference lies in the delivery device and potentially the inactive ingredients. Wixela Inhub uses a multi-dose dry powder inhaler device, while Advair Diskus uses a similar dry powder inhaler.
What is the typical dosage for Wixela Inhub?
The typical dosage of Wixela Inhub for asthma is one inhalation twice daily. For COPD, the dosage is also one inhalation twice daily. It is crucial to use Wixela Inhub as prescribed by a healthcare professional, as the dosage and frequency may be adjusted based on individual patient needs and disease severity.
Sources:
1. https://www.goodrx.com/wixela-inhub
2. https://www.wixelahcp.com/savings-and-support
3. https://drugpatentwatch.com/
4. https://www.rxlist.com/wixela-inhub-drug.htm